Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 4/20 | 0.55 |
| ▸ | CA2 | P00918 | 4/20 | 0.55 |
| ▸ | CA7 | P43166 | 2/20 | 0.55 |
| ▸ | CA9 | Q16790 | 2/20 | 0.55 |
| ▸ | CA12 | O43570 | 1/20 | 0.55 |
| ▸ | CA4 | P22748 | 1/20 | 0.55 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.55 |
| ▸ | ACHE | P22303 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.50 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | IDO1 | P14902 | 1/20 | 0.50 |
| ▸ | TDO2 | P48775 | 1/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.47 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.47 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL334556 | 1.00 | CA1 (0.55) | CA1CA2CA7CA9CA12 | |
| SCHEMBL29471011 | 1.00 | CA1 (0.55) | CA1CA2CA7CA9CA12 | |
| SCHEMBL1257092 | 1.00 | CA1 (0.55) | CA1CA2CA7CA9CA12 | |
| SCHEMBL21377269 | 1.00 | CA1 (0.55) | CA1CA2CA7CA9CA12 | |
| SCHEMBL29705638 | 1.00 | CA1 (0.55) | CA1CA2CA7CA9CA12 | |
| Hydrochloric Acid SCHEMBL20746349 | 0.98 | IDO1 (0.53) | CA1CA2CA7CA9CA12 | |
| Hydrochloric Acid SCHEMBL28055201 | 0.98 | IDO1 (0.53) | CA1CA2CA7CA9CA12 | |
| Iodide SCHEMBL28805507 | 0.98 | CA1 (0.52) | CA1CA2CA7CA9CA12 | |
| Hydrochloric Acid SCHEMBL1168978 | 0.98 | IDO1 (0.53) | CA1CA2CA7CA9CA12 | |
| SCHEMBL19668658 | 0.90 | CA1 (0.50) | CA1CA2CA7CA9CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 125 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2019058290-A1 | IMPROVED PROCESS FOR THE PREPARATION OF OZANIMOD Α-AMINO COMPOUND | SUVEN LIFE SCIENCES LIMITED (IN) | 2019-03-28 | — | — | WO | claimed |
| US-8084630-B2 | Process for the synthesis of ramelteon and its intermediates | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2011-12-27 | — | — | US | claimed |
| US-20090281176-A1 | PROCESS FOR THE SYNTHESIS OF RAMELTEON AND ITS INTERMEDIATES | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2009-11-12 | — | — | US | claimed |
| EP-2098519-A1 | Process for the synthesis of ramelteon and its intermediates | Teva Pharmaceutical Industries Ltd. (IL) | 2009-09-09 | — | — | EP | claimed |
| US-20090069581-A1 | PROCESS FOR THE SYNTHESIS OF RAMELTEON AND ITS INTERMEDIATES | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2009-03-12 | — | — | US | claimed |
| US-12527779-B2 | Prostaglandin E2 (PGE2) EP4 receptor antagonists | DOMAIN THERAPEUTICS (FR) | 2026-01-20 | — | — | US | disclosed |
| US-20250066364-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIMIDINES AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS | BIAL R&D INVEST S A (PT) | 2025-02-27 | — | — | US | disclosed |
| EP-4469431-A1 | 4-SUBSTITUTED-PHENYL ACETAMIDES AND ARYLUREAS AS AGONISTS FOR THE ORPHAN RECEPTOR GPR88 | Research Triangle Institute (US) | 2024-12-04 | — | — | EP | disclosed |
| EP-4406616-A2 | SUBSTITUTED PYRAZOLO(1,5-A)PYRIMIDINES AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS | Bial-R&D Investments, S.A. (PT) | 2024-07-31 | — | — | EP | disclosed |
| US-11932645-B2 | Substituted pyrazolo[1,5-a]pyrimidines and their use in the treatment of medical disorders | Bial—R & D Investments, S.A. (PT) | 2024-03-19 | — | — | US | disclosed |
| EP-4038052-B1 | PROSTAGLANDIN E2 (PGE2) EP4 RECEPTOR ANTAGONISTS | DOMAIN THERAPEUTICS (FR) | 2024-02-07 | — | — | EP | disclosed |
| US-20240009169-A9 | PPARG Modulators for the Treatment of Osteoporosis | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED | 2024-01-11 | — | — | US | disclosed |
| US-20050080267-A1 | Synthesis of enantiomerically pure amino-substituted fused bicyclic rings | ANORMED, INC. (CA) | 2005-04-14 | — | — | US | disclosed |
| EP-1487795-A4 | SYNTHESIS OF ENANTIOMERICALLY PURE AMINO-SUBSTITUTED FUSED BICYCLIC RINGS | ANORMED INC (CA) | 2005-02-09 | — | — | EP | disclosed |
| EP-1487795-A2 | SYNTHESIS OF ENANTIOMERICALLY PURE AMINO-SUBSTITUTED FUSED BICYCLIC RINGS | ANORMED INC. (CA) | 2004-12-22 | — | — | EP | disclosed |
| US-6825351-B2 | SELECTIVE HYDROGENATION OF AMINO-SUBSTITUTED FUSED BICYCLIC AROMATIC RING SYSTEM, PREPARATION OF RACEMIC AMINO SUBSTITUTED FUSED BICYCLIC RING SYSTEM VIA NITROSATION, ENZYMATIC RESOLUTION OF RACEMIC MIXTURE TO PRODUCE (R)- AND (S)-FORMS | ANORMED, INC. (CA) | 2004-11-30 | — | — | US | disclosed |
| US-20030114679-A1 | Synthesis of enantiomerically pure amino-substituted fused bicyclic rings | ANORMED CORPORATION (CA) | 2003-06-19 | — | — | US | disclosed |
| WO-2003022785-A2 | SYNTHESIS OF ENANTIOMERICALLY PURE AMINO-SUBSTITUTED FUSED BICYCLIC RINGS | ANORMED INC. (CA) | 2003-03-20 | — | — | WO | disclosed |
| US-6350907-B1 | PEPTIDE ENZYME INHIBITORS | PFIZER INC | 2002-02-26 | — | — | US | disclosed |
| US-5300437-A | Using omega-amino acid transaminase | CELGENE CORPORATION (US) | 1994-04-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090281176-A1 | PROCESS FOR THE SYNTHESIS OF RAMELTEON AND ITS INTERMEDIATES | CYP2B6, UGT1A6, CYP2A6 | CA1 3955/4885CA2 3084/4885CA7 2028/4885 |
| US-12527779-B2 | Prostaglandin E2 (PGE2) EP4 receptor antagonists | PTGER1, PTGER4, PTGER3 | CA1 1567/4885CA2 729/4885CA7 1644/4885 |
| US-20030114679-A1 | Synthesis of enantiomerically pure amino-substituted fused bicyclic rings | CBR1, POR, CBR3 | CA1 2594/4885CA2 2360/4885CA7 2590/4885 |
| US-11932645-B2 | Substituted pyrazolo[1,5-a]pyrimidines and their use in the treatment of medical disorders | PARK7, PNP, GAA | CA1 4823/4885CA2 4792/4885CA7 4098/4885 |
| US-20050080267-A1 | Synthesis of enantiomerically pure amino-substituted fused bicyclic rings | CBR1, POR, CBR3 | CA1 2594/4885CA2 2360/4885CA7 2590/4885 |
| US-20090069581-A1 | PROCESS FOR THE SYNTHESIS OF RAMELTEON AND ITS INTERMEDIATES | CYP2B6, UGT1A6, CYP2A6 | CA1 2650/4885CA2 1963/4885CA7 1770/4885 |
| US-20250066364-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIMIDINES AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS | PARK7, PNP, GAA | CA1 4823/4885CA2 4792/4885CA7 4098/4885 |
| US-20240009169-A9 | PPARG Modulators for the Treatment of Osteoporosis | PPARG, PPARA, PPARD | CA1 4854/4885CA2 4357/4885CA7 4706/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.